Hints and tips:
...As well as proceeds from its Covid products, Pfizer has also benefited from the spin-off of its Upjohn generics business, which combined with Mylan to form Viatris in late 2020....
...The Swiss pharmaceuticals group is following many rivals to focus its operations on higher-value innovative treatments rather than the cheaper off-patent drugs made by Sandoz, including generic versions...
...Gilead told the FT that in India the price of the drug and the terms of supply are negotiated by the US company Viatris, previously also known as Mylan, which holds the marketing authorisation for AmBisome...
...Results and forecasts exclude its Upjohn unit, as Pfizer closed the transaction to merge the generics business with Mylan during the quarter....
...The US District Court for the Northern District of West Virginia decided in favour of AstraZeneca in litigation against Mylan Pharmaceuticals and Kindeva, the company said....
...Mylan, a US-based generics maker, has restarted production of hydroxychloroquine at its West Virginia plant and is looking to increase manufacturing outside of the US too....
...In mid-afternoon trading in New York, shares in Mylan, which is in the process of merging with Pfizer’s generics business Upjohn, were up 2.6 per cent to $22.83....
...Teva, Mylan and others in the lawsuits have denied wrongdoing....
...Novartis said it had enough active pharmaceutical ingredients for 80m doses, while Mylan, which manufactures in the US, said it had enough for 50m. Teva did not respond to a request for comment....
...Drugmakers, including Novartis, Sanofi, Teva and Mylan, have said they would ramp up production of the drug and distribute it for compassionate use....
...The deal with Mylan is similar. Here, however, Pfizer is spinning off Upjohn and then combining it with all of Mylan....
...It was formed in November from a combination of Mylan and Pfizer’s Upjohn unit, creating a large company focused on selling generics, particularly outside the US....
...To stave off shortages, generic drugmakers like Mylan are ramping up production....
...Investors will seek updates on Pfizer’s deal with Mylan on Thursday, while AbbVie’s acquisition of Allergan, which is nearing completion, will be in focus on Friday....
...Merck is the latest pharmaceutical company to try to streamline its business to focus on higher-growth — and usually higher-priced — drugs....
...Large generics manufacturers including Mylan and Teva Pharmaceutical would not comment on potential supply chain problems....
...Last quarter, the company said sales of its multiple sclerosis drug were worse than expected, and it failed to received approval to make a generic version of Advair, an asthma medicine developed by UK pharmaceutical...
...Pfizer has reached a deal to spin off its Upjohn unit and combine it with generics drugmaker Mylan to create an off-patent pharmaceutical group with an enterprise valuation of about $50bn....
...For all Mylan stakeholders, half a decade seems like a lifetime ago....
...The pharmaceutical company reported non-gaap earnings per share of $1.30 in the quarter, lower than the average analyst estimate of $1.36 and down 9 per cent year-on-year....
...The expanded complaint comes as pharmaceutical companies are under political pressure to bring down high drug prices....
..., for $63bn; Pfizer’s sale of its off-patent drug business to Mylan for $9.5bn; and Roche’s $4.8bn takeover of gene therapy company Spark Therapeutics....
...In 2015, he advised Mylan on a successful defence against a hostile bid by Teva Pharmaceuticals....
...Mylan, which makes a generic version of Truvada, pays royalties for some its sales to the CDC. When the generic market forms in the US, it said, it will continue to do so....
...In August, the FDA granted approval to Teva Pharmaceuticals for the first generic versions of the EpiPen and EpiPen Jr, introducing off-brand competitors to a key Mylan product line....
International Edition